A combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses will lower blood pressure more effectively than initiating patients with standard dose monotherapy as per current guideline-recommended therapy.
A 12-week double blind randomised controlled trial comparing ultra-low dose quadruple combination therapy (LDQT) with standard dose irbesartan in participants with grade 1 and 2 essential hypertension with 12 months extension substudy to assess longer term effects and tolerability.
The QUARTET study is being conducted at various sites across the country:
Royal North Shore Hospital
Holdsworth House Medical Centre, Darlinghurst
Castle Hill Medical Centre, Castle Hill
Kildare Road Medical Centre, Blacktown
Royal Perth Hospital
Sir Charles Gairdner Hospital
University of Tasmania
Ethics approval number: HREC Ref: HREC/15/WMEAD/422
The Study is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12616001144404. The ANZCTR is an open access registry that the public can use for further information.
You may be eligible to participate in this study if you HAVE the inclusion criteria and DON’T HAVE the exclusion criteria:
And one of the following:
If you are interested in taking part in the study please contact us:
Email : Warc.Quartet@sydney.edu.au
Telephone: 02 8627 3578